Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$14.39 USD
-0.23 (-1.57%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $14.39 0.00 (0.00%) 5:04 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KROS 14.39 -0.23(-1.57%)
Will KROS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KROS
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KROS
ClearBridge Small Cap Strategy Q2 2025 Commentary
Noteworthy Friday Option Activity: KROS, TEAM, BYON
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
Major Shareholder Sells Off Keros Therapeutics Stock!
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls